Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431593 | 0.80 | HRH3 (0.39) | CYP1A2CYP3A4CYP2C19MAOBHRH3 | |
| SCHEMBL2434988 | 0.79 | MAOB (0.42) | MAOAMAOBKMT2AKDRHRH3 | |
| SCHEMBL2432181 | 0.75 | HPGD (0.43) | CYP1A2KDRHRH3ATM | |
| SCHEMBL2462928 | 0.73 | PDE5A (0.41) | HRH3GSK3B | |
| SCHEMBL2461065 | 0.71 | KDM4E (0.40) | KDRHRH3 | |
| SCHEMBL1135960 | 0.70 | MAOB (0.41) | CYP3A4MAOAMAOBKMT2AKDR | |
| SCHEMBL2433158 | 0.70 | ALDH1A1 (0.39) | CYP3A4MAOAMAOBKMT2AHRH3 | |
| SCHEMBL2435481 | 0.69 | CYP19A1 (0.41) | CYP19A1MAOAMAOBCYP11B1CYP11B2 | |
| SCHEMBL2432282 | 0.69 | NPC1 (0.37) | CYP3A4MAOAMAOBKMT2AMEN1 | |
| SCHEMBL2432159 | 0.69 | NPC1 (0.37) | CYP3A4KMT2AKDRHRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | CYP19A1 2317/4885CYP1A2 1581/4885CYP3A4 2014/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | CYP19A1 2317/4885CYP1A2 1581/4885CYP3A4 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.